Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020-2024).

Gandhi K, Joga R, Sowndharya M, Vijay GK, Waiker S, Yerram S, Raghuvanshi RS, Srivastava S

DOI: 10.1007/s43441-025-00831-w
Published: 2025 Nov
Container: Therapeutic innovation & regulatory science
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s43441-025-00831-w,
  title = {Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020-2024).},
  author = {Gandhi K and Joga R and Sowndharya M and Vijay GK and Waiker S and Yerram S and Raghuvanshi RS and Srivastava S},
  year = {2025},
  journal = {Therapeutic innovation \& regulatory science},
  doi = {10.1007/s43441-025-00831-w},
  url = {https://doi.org/10.1007/s43441-025-00831-w}
}

RIS

TY  - JOUR
TI  - Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020-2024).
AU  - Gandhi K
AU  - Joga R
AU  - Sowndharya M
AU  - Vijay GK
AU  - Waiker S
AU  - Yerram S
AU  - Raghuvanshi RS
AU  - Srivastava S
PY  - 2025
JO  - Therapeutic innovation & regulatory science
DO  - 10.1007/s43441-025-00831-w
UR  - https://doi.org/10.1007/s43441-025-00831-w
ER  -

APA

K, G., R, J., M, S., GK, V., S, W., S, Y., RS, R., & S, S. (2025). Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020-2024).. Therapeutic innovation & regulatory science. https://doi.org/10.1007/s43441-025-00831-w

Source records

pubmed · retrieved 2026-09-26T23:52:23.936Z